Acetaminophen is the most widely used antipyretic and
analgesic. It is a combination agent in approximately
125 medications that has been deemed safe and
effective when used within recommended dosage. Its
therapeutic safety in children has been directly related
to absence of significant cumulative kinetics. In USA,
203,930 cases of actaminophen over ingestion were
reported to US poison centers between 1998 and 1999,
making it the leading pharmacologic agent associated
with toxicity.1 It is freely available in the market and
its use is widely known to general public. Careless
approach of family members towards its use and
storage results in high incidence of accidental overdose
in children particularly below the age of 6 years, less
common but potentially more devastating is the suicide
attempt as manipulative episode in the adolescent.
Experience with acetaminophen overdosages further
indicates a considerable difference between the child
under age 6 years and adolescent.2 Following ingestion
metabolized in liver with less than 2% being excreted
unchanged in urine.4
In children, between 9 to 12 years of age, acetaminophen
is primarily metabolized in the liver to the sulfate
or glucuronide conjugates which are metabolically inert.
The remaining 2 to 4% is metabolized through
cytochrome p-450 mixed functions oxidase system
which conjugates it with glutathione to produce
mercaptopuric acid, a non-toxic product. The lower
incidence of toxicity in young children may be related
to lesser metabolism via p-450.5
With acetaminophen overdose, when hepatic stores
of glutathione are depleted to less than 70% of normal,
the highly reactive intermediate toxic metabolites bind
with hepatic macromolecules and cause hepatic
necrosis.6 Hepatic enzyme induction by barbiturates,
narcotics, hydantoin and histamines may increase the
formation of reactive metabolites, predisposing the
patient to hepatic damage even if a minor overdose of
acetaminophen is ingested.7 Co-ingestion of ethanol and
acetaminophen is cytoprotective in both adults and
children, probably as a result of competition at P-450
site but ethanol is not recommended as therapy.8
Chronic acetaminophen poisoning is rare as
approximately 98% of the drug is metabolized by liver,
children receiving therapeutic doses of acetaminophen
over a long time should have no difficulty in managing
the small load of toxic metabolites with constantly
regenerating glutathione stores in liver. Therapeutic
accumulation to plasma levels of 40 μg/dl which is
still under that required for hepatotoxicity may occur
if the highest recommended dose of 15 mg/kg is given
every 4 hours for extended period, child abuse or
intentional overdose must be considered in children
who develop high plasma levels at therapeutic
overdose.9
Clinical Features
Children with overdose of acetaminophen usually
present with features of hepatic cell damage, renal
tubular necrosis and hypoglycemic coma. They pass
through following four stages of toxicity if left
untreated.10
Stage I: This stage lasts for first 24 hours after
ingestion. Average time of onset of symptoms
is 6 hours after ingestion and children usually
become symptomatic by 14 hours. In this
stage child usually presents with anorexia,
nausea, vomiting, malaise, pallor and
diaphoresis, children less than 6 years of age
rarely show diaphoresis but present with
early vomiting. Laboratory investigations
such as ALT, AST, serum bilirubin and
prothrombin time are normal in this stage.
Stage II: This stage lasts for next 24 hours after
stage I. It is characterized by resolution of
symptoms of stage I with upper quadrant
abdominal pain and tenderness. Mild
hepatomegaly and jaundice may also be
present. Laboratory investigations show
elevated serum bilirubin, AST, ALT and
prothrombin time. Some children may
develop oliguria.
Stage III: This stage is seen 48 hours to 96 hours after
ingestion. Maximum liver functions abnormalities
are seen during this period.
Hepatotoxicity due to acetaminophen is
characterized by elevated transaminases,
increased serum bilirubin and prolonged
prothrombin time.
Plasma AST level in excess of 1000 IU/L,
prolongation of prothrombin time and serum
bilirubin more than 4 mg/dL on 3rd to fifth
day after ingestion are indicators of severe
toxicity.11 Acute renal failure may also occur
in some patients. Anorexia, nausea, vomiting
and malaise may reappear during this stage.
Less than 1% of patients in stage III develops
fulminant hepatotoxicity and eventually dies
of hepatic failure, if left untreated. Liver
biopsy in this stage reveals centrilobular
necrosis of hepatocytes with sparing of
periportal area.
Stage IV: This is the stage of resolution and extends
from 4 days to two weeks. It is characte-rized
by resolution of hepatic dysfunction although
AST may remain elevated for few more days.
On follow up of patients who had hepatotoxicity,
usually revealed no sequelae either
clinically or on liver biopsy, three months to
one year later.
Diagnosis
1. History of ingestion
2. Clinical features
3. Laboratory investigations
a. Plasma level of acetaminophen to assess the
severity of hepatotoxicity: Serum concentrations
greater than 200, 100 and 50 μg/ml at 4, 8 and 12
hours after ingestion respectively or any
concentration above the values depicted on the
Rumack Mathew normogram indicates a potential
risk of hepatotoxicity.2
b. Plasma AST level greater than 1000 IU/L
c. Bilirubin more than 4 mg/dL
d. Prolonged prothrombin time.
Management
1. Assessment: In children with acetaminophen
overdose, efforts should be made to determine the
amount of drugs or other co-ingestants which may
also have been involved. Acetaminophen alone will
not produce any alteration in the sensorium in first
24 hours and usually will not produce such an
alteration unless patient develops hepatic
encephalopathy. Thus, if a patient comes with a
significant change in sensorium, some other agents
should be considered in addition to or instead of
acetaminophen care of airways, breathing and
circulation should be done properly. A sample of
blood should be drawn and sent for laboratory
investigations including serum acetaminophen level.
2. General measures: When a child presents with a
history acetaminophen overdose within 4 hours,
gastrointestinal decontamination should be done.
Emesis should be induced with syrup of ipecac to
get rid of remaining acetaminophen. Gastric lavage
must be done with normal saline. Activated charcoal
is effective in adsorbing acetaminophen. In physiological
pH range, adsorption is rapid and pH
independent.12 The dose of activated charcoal is
10 times the ingested dose of acetaminophen.
Activated charcoal appears to reduce the number of
patients who achieve toxic acetaminophen concentrations
and thus may reduce the need for treatment
and hospital stay.13 For maximal effect, activated
charcoal should be administered within 30 minutes
of ingestion. However, in vitro experiments, activated
charcoal effectively adsorbs both methionine and
N-acetylcysteine, concurrent administration of
both would markedly diminish their antidotal
effectiveness.14
Specific Measures
N-acetylcysteine is the specific antidote and drug of
choice for prevention of hepatotoxicity. Other drugs like
methionine, cysteamine are available but are not popular
due to their side effect. Oral or intravenous N-acetyl
cysteine mitigates acetaminophen induced hepatorenal
damage as demonstrated by prevention of elevation of
serum transamiases, bilirubin and prolongation of
prothrombin time, if given within 10 hours but becomes
less effective thereafter. In vivo, N-acetyl cysteine forms
L-cysteine, cystine, L-methionine, glutathione and mixed
disulfides; L-methionine also forms cysteine thus giving
rise to glutathione and other products.15 The beneficial
effects of N-acetyl cysteine include improvement of liver
blood flow, glutathione replenishment, modification of
cytokine production and free radical oxygen
scavenging.16
The oral dosage schedule of N-acetylcysteine is
140 mg/kg of body weight as loading dose followed by
subsequent doses of 70 mg/kg body weight at 4 hourly
intervals for an additional 17 doses.17 If the patient
vomits within an hour of administration of dose, it
should be repeated. If there is persistent vomiting, a
nasogastric tube should be inserted, preferably into the
duodenum. The optimal route and duration of
administration of N-acetylcysteine are controversial. On
the basis of selected Post-hoc analysis, oral N-acetyl
cysteine was found superior to intravenous route in
presentations later than 15 hours. However, the
differences claimed between oral and intravenous Nacetylcysteine
regimes are probably artifactual and relate
to inappropriate subgroup analysis. A shorter hospital
stay, patient and doctor convenience and the concerns
over the reduction in bioavailability of oral Nacetylcysteine
by charcoal and vomiting make
intravenous N-acetylcysteine preferable for most patients
with acetaminophen poisoning (Table 49.4.1).18 The
administration of activated charcoal before oral N-acetyl
cysteine in acetaminophen overdose does not reduce the
efficacy of N-acetylcysteine and may provide additional
hepatoprotective benefit. However, some workers have
suggested increment of loading dose by 40% or from
140 mg/kg to 235 mg/kg body weight.19
As unpleasant odor and frequent vomiting is
associated with its use, the concentration of N-acetylcysteine
should be diluted to a final concentration of
5%(w/v) and to mask the unpleasant flavor, citrus fruit
juices or carbonated beverages should be added with
intravenous preparations loading dose should be given
with 200 ml of 5% dextrose over 15 minutes followed
by subsequent doses in 500 ml dextrose over 4-8 hours.
Table 49.4.1: Biochemical and hematological
abnormalities in paracetamol poisoning
Biochemical ↑ ALT/AST
↑ Bilirubin
↓ Blood glucose
↓ Lactase
↑ Amylase
↑ Creatinine
↓ Phosphate
Hematological Thrombocytopenia
↑ Prothrombin time
↓ Clotting factors II, V, VII
Management of Specific Toxicological Emergencies 47477777
Nausea, vomiting and diarrhea may also occur as
results of oral N-acetylcysteine administration.
Anaphylactoid reactions including angioedema,
bronchospasm, flushing, hypotension, hypokalemia,
nausea/vomiting, rashes, tachycardia and respiratory
distress may occur 15-60 minutes after N-acetylcysteine
infusion in up to 10% of patients. A reduction in the
loading dose of N-acetylcysteine may reduce the risk
of adverse reactions while maintaining efficacy.15 Oral
therapy with N-acetylcysteine or methionine for
acetaminophen poisoning is contraindicated in presence
of coma or vomiting or if activated charcoal has been
given by mouth. Hemodynamic and oxygen delivery
and utilization parameters must be monitored carefully
during delayed N-acetylcysteine treatment of patients
with fulminate hepatic failure, as unwanted
vasodilatation may be deleterious to the maintenance
of mean arterial blood pressure.16
The administration of N-acetylcysteine for longer
period might provide enhanced protection for patients
in whom acetaminophen absorption or elimination is
delayed. N-acetylcysteine may also have a role in
treatment of toxicity from carbon tetrachloride, chloroform,
1, 2-dichloropropane and other compounds.15
Methionine acts by replenishing cellular glutathione
stores or more probably through generation of cysteine
and/or glutathione. It acts also as a source of sulfate
and so unsaturates sulfate conjugation. Methionine is
more effective when given orally than IV. The initial
dose is 2.5 gm then 2.5 gm 4 hourly to a total of 10 gm
over 12 hours.14
During the course of treatment, laboratory investigations
should be repeated. If the liver function tests
begin to become abnormal, proper measures should be
taken. Once hepatic failure occurs, use of N-acetylcysteine
is contraindicated15 and patient should be
managed along conventional line with lactulose, vit-K,
20% mannitol and appropriate IV fluids. Renal function
should be evaluated periodically and necessary
measures should be taken, if deterioration occurs.
Forced alkaline diuresis is of no therapeutic value.
Hemodialysis or charcoal hemoperfusion enhances
elimination of acetaminophen but not the toxic
metabolites.
Prognosis
The poor prognostic factors in established paracetamol
induced hepatic failure are pH below 7.3, serum
creatinine above 300 μmol/L and prothrombin time
above 100 seconds in grade III to IV encephalopathy.
However, factor VIII to factor V ratio above 30 is the
best poor prognostic indicator.16
REFERENCES
1. Clark J. Acetaminophen poisoning and the use of
intravenous N-acetylcysteine. Air Med J 2001;20:7-16.
2. Rumack BH, Mathew H. Acetaminophen poisoning and
toxicity. Pediatrics 1975;55:871-6.
3. Peterson RG, Rumack BH. Age as variable in acetaminophen
overdose. Arch Intern Med 1981; 141:390-3.
4. Rumack BH. Acetaminophen overdose in young
children. Am J Dis Child 1984;138:428-33.
5. Lich Lai MW, Sarnaik AP, Newton JE. Metabolism and
pharmacokinetics of acetaminophen in severely
poisoned young child. J Pediatr 1984;105:125-8.
6. Mitchell JR, Thorgeirsson SS, Potter NZ. Acetaminophen
induced hepatic injury. Clin Pharmacol Ther 1974; 16:676.
7. Miller RP, Robert RJ, Fisher LJ. Acetaminophen
elimination kinetics in neonates, children and adults.
Clin Pharmacol Ther 1976;19:284-94.
8. Rumack BH. Acetaminophen overdosage in young
children, treatment and effects of alcohol and additional
ingestions in 417 cases. Am J Dis Child 1984;138:428-33.
9. Nahata Mc, Powel DA, Durell DE. Acetaminophen
accumulation in a pediatric patient after repeated
therapeutic doses. Eur J Clin Pharmacol 1984;27:57-9.
10. Rumack BH, Peterson RC, Koch GG. Acetaminophen
overdose: 662 cases with evaluation of oral acetylcysteine
treatment. Arch intern Med 1981;141:380-5.
11. James O, Lesna M, Roberts SH. Liver damage after
paracetamol overdosage: comparison of liver function
tests, fasting serum bile acids and liver histology. Lancet
1975;2:579-81.
12. Riper W, Piperno E, Mosher AH, Berrssenbruesse DA.
Pathophysiology of acute acetaminophen toxicity:
implication for management. Pediatrics 1978;62:880-9.
13. Buckley NA, Whyte IM, O’Connell DL, Dawson AH.
Activated charcoal reduces the need for N-acetylcysteine
treatment after acetaminophen overdose. J Toxicol Clin
Toxicol 1998;37:753-7.
14. Klein-Schwartz W, Oderda GM. Adsorption of oral
antidotes for acetaminophen poisoning (methionine or
N-acetylcysteine) by activated charcoal. Clin Toxicol
1981;18:283-90.
15. Flanagan RJ, Meredith TJ. Use of N-acetylcysteine in
clinical toxicology. Am J Med 1991;91:131-9.
16. Jones AL. Mechanism of action and value of N-acetylcysteine
in the treatment of early and late acetaminophen
poisoning: a critical review. J Toxicol Clin Toxicol
1998;36:277-85.
17. Smilkstein MJ, Knapp GL, Kuling KW, Rumack BH.
Efficacy of oral N-acetylcysteine in the treatment of
acetaminophen overdose. Analysis of national multicenter
study (1976 to 1985). N Engl J Med 1988; 319:1557-62.
18. Buckley NA, Whyte IM, O’Connell DL, Dawson AH.
Oral or intravenous N-acetylcysteine: which is the
treatment of choice for acetaminophen (paracetamol)
poisoning? J Toxicol Clin Toxicol 1991;37:759-67.
19. Chamberlain JM, Gorman RL, Oderda GM, Klein-Schwartz
W, Ktein BL. Use of activated charcoal in a simulated
poisoning with acetaminophen: a new loading dose for
N-acetylcysteine? Ann Emerg Med 1993;22:1398-402.
No comments:
Post a Comment
اكتب تعليق حول الموضوع